Tunlametinib

DB18791InvestigationalSmall molecule

Tunlametinib: Overview.

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₁₆H₁₂F₂IN₃O₃S · 491.25 g/mol (avg)
Code names: HL-085

Resolves to

Compound

Structure

InChIKeyUFZJUVFSSINETF-UHFFFAOYSA-NSMILESOCCONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C2N=CSC2=C1

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

21Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tunlametinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.